Genomics & Genetics Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics & Genetics Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business Update
AstraZeneca selects preferred supplier of siRNA
July 30th, 2004
QIAGEN N.V. (NASDAQ: QGENF; Frankfurt, Prime Standard: QIA) announced that it has entered into a supply agreement for siRNA molecules with AstraZeneca (NYSE: AZN). Under the terms of this agreement QIAGEN will be the preferred supplier to AstraZeneca for siRNA products used in gene silencing applications. Financial terms were not disclosed. "We are pleased that AstraZeneca has chosen QIAGEN as its preferred supplier for RNAi based gene silencing experiments", said Dr. Ulrich Schriek, QIAGEN's vice president corporate business development. "QIAGEN's proprietary siRNA design based on TOM-amidites in combination with its state-of-the-art synthesis...
Source: Genomics & Genetics Weekly (2004-07-30)
|
